RxDoctor Payments Data

Nicholas Perryman

Psychiatric/Mental Health · Springfield, MONPI 1760058424

Payments from drug & device makers

$5,354in general payments, 2019–2025

Across 311 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$583
  • Alkermes, Inc.$560
  • Johnson & Johnson$554
  • Otsuka America Pharmaceutical, Inc.$508
  • Neurocrine Biosciences, Inc.$477
  • AbbVie$437
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$5,21297%
  • Education$1423%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,354 in reported general payments places this provider in the 85th percentile of 565 psychiatric/mental health providers in Missouri.

See all psychiatric/mental health providers in Missouri

Medicare billing

Part B allowed, 2024
$17,938
Medicare patients
53
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$103,748
Invega SustennaPaliperidone Palmitate24$81,057
VraylarCariprazine Hcl39$55,076
LybalviOlanzapine/Samidorphan Malate25$42,174
AristadaAripiprazole Lauroxil11$35,001
FanaptIloperidone14$26,491
NuedextaDextromethorphan Hbr/Quinidine17$23,515
BelsomraSuvorexant39$17,796
Divalproex Sodium ErDivalproex Sodium203$12,015
Asenapine Maleate35$11,792
Clozapine109$10,039
Atomoxetine Hcl56$7,649
Aripiprazole153$7,128
Vilazodone Hcl46$6,244
Olanzapine214$6,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$477$103,74813 claims
Johnson & JohnsonInvega Sustenna$554$81,05724 claims
Alkermes, Inc.Lybalvi, Aristada$560$77,17536 claims
AbbVieVraylar$437$55,07639 claims
Vanda Pharmaceuticals Inc.Fanapt$423$26,49114 claims
Avanir Pharmaceuticals, Inc.Nuedexta$41$23,51517 claims
MerckBelsomra$12$17,79639 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$176$5,21111 claims
Teva Pharmaceuticals USA, Inc.Loxapine$327$5,086102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 565 psychiatric/mental health providers in Missouri.

Other psychiatric/mental health in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →